Akebia Therapeutics
AKBA
#8131
Rank
HK$2.65 B
Marketcap
HK$9.88
Share price
-3.08%
Change (1 day)
-67.31%
Change (1 year)

Earnings for Akebia Therapeutics (AKBA)

Earnings in 2026 (TTM): -HK$0.15 Billion

According to Akebia Therapeutics's latest financial reports the company's current earnings are HK$0.23 Billion. In 2025 the company made an earning of -HK$29.18 Million, an increase over its 2024 earnings that were of -HK$0.55 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Akebia Therapeutics from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -HK$0.15 Billion402.03%
2025 -HK$29.18 Million-94.64%
2024 -HK$0.55 Billion33.68%
2023 -HK$0.41 Billion-45.12%
2022 -HK$0.75 Billion-66.55%
2021 -HK$2.22 Billion-26.24%
2020 -HK$3.01 Billion33.94%
2019 -HK$2.25 Billion66.52%
2018 -HK$1.35 Billion123.53%
2017 -HK$0.61 Billion-43.34%
2016 -HK$1.07 Billion123.58%
2015 -HK$0.48 Billion63.95%
2014 -HK$0.3 Billion181.24%
2013 -HK$0.11 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Johnson & Johnson
JNJ
HK$203.69 B-138,573.43%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
HK$123.75 B-84,231.98%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Amgen
AMGN
HK$71.24 B-48,535.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Nektar Therapeutics
NKTR
-HK$1.2 Billion 711.30%๐Ÿ‡บ๐Ÿ‡ธ USA